555.05↑2.70 (0.49%)
02:39 PM,25th Sep 2023553.65↑1.50 (0.27%)
02:55 PM,25th Sep 2023BSE : 524348
NSE : AARTIDRUGS
Sector : Health care
ISIN Code : INE767A01016
Last Updated: Sep 25 2023 | 02:55 PM IST
Market Cap (₹ Cr) | 5139 |
Turnover (₹ Cr) | 0.69 |
Volume (Shares) | 124047 |
Face Value | 10 |
52-WK High | 645.75 |
52-WK High Date | 25 Jul 2023 |
52-WK Low | 313.90 |
52-WK Low Date | 20 Mar 2023 |
All Time High | 1026.95 |
All Time High Date | 08 Oct 2020 |
All Time Low | 0.95 |
All Time Low Date | 08 Dec 1997 |
Aarti Drugs Limited (ADL) is a prominent manufacturer of APIs Pharma Intermediates and Specialty Chemicals. The Company operates as part of the Aarti Group a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics Anti Protozoal Anti-Inflammatory Anti-diabetic Anti Fungal and Cardioprotectant therapeutic segments the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions one in Tarapur and the other in Turbhe Maharashtra. It has 3 subsidiaries namely Pinnacle Life Science Private Limited Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs) Steroids Pharmaceutical Intermediates and Specialty Chemicals such as Benzene Sulphonyl Chloride Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd a part of Aarti Group of Industries was incorporated in September 28th 1984. In the year 1993 the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95 the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also Rupal Chemical Industries a group company was amalgamated with the company.During the year 1996-97 the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01 they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03 the company expanded the production capacity of bulk drugs by 598000 kg to 17430000 kg. During the year 2003-04 the company further expanded the production capacity of bulk drugs by 588000 kg to 18018000 kg. During the year 2004-05 the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06 the company increased the production capacity of Pharmaceutical by 2325000 kg to 24020000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 2006-07 the company increased the production capacity by 570000 kg to 24590000 kg. During the next year they increased the production capacity by 399000 kg to 24989000 kg. During the year 2008-09 they further increased the production capacity of Pharmaceutical by 50000 kg to 25000000 kg.During the year 2009-10 the company carried out research and development work/ process improvement work in bulk drugs such as antihistaminic/anti-allergic anti-inflammatory and anti-diabetic. ADL has exported intermediates such as Stage-I of pioglitazone and AU-% for tamsulosin and have expanded the production capacity from 25000000 kg to 25716000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd. wholly owned subsidiary of the Company with the Company became operative w.e.f. from 1st April 2011 being the Appointed Date upon filing of High Court Order sanctioning the said Scheme with the Registrar of Companies on 6th July 2012.During year 2015 Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd. situated at Baddi Himachal Pradesh. During the year 2020 Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA incorporated in Santiago Chile was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary) located in Mumbai was founded for carrying on the business of manufacturers producers processors buyers sellers importers exporters and/ or otherwise dealers in Speciality and other chemicals pharmaceuticals and drugs. During the year 2021 Pinnacle Life Science LLC Wholly Owned Subsidiary was wound up/ closed as said Company did not have any business activity.In 2022 the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur which turned operational effective from May 2022.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 5139 |
EPS - TTM (₹) [S] | 17.93 |
P/E Ratio (X) [S] | 4.61 |
Face Value (₹) | 10 |
Latest Dividend (%) | 10.00 |
Latest Dividend Date | 08 Feb 2023 |
Dividend Yield (%) | 0.18 |
Book Value Share (₹) [S] | 120.34 |
P/B Ratio (₹) [S] | 4.61 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
DSP Small Cap Fund (IDCW) | 198.10 | 3460817 | 1.64 |
DSP Small Cap Fund - Direct (IDCW) | 198.10 | 3460817 | 1.64 |
DSP Small Cap Fund - Direct (G) | 198.10 | 3460817 | 1.64 |
DSP Small Cap Fund (G) | 198.10 | 3460817 | 1.64 |
DSP Healthcare Fund (G) | 42.22 | 737671 | 2.57 |
DSP Healthcare Fund (IDCW) | 42.22 | 737671 | 2.57 |
DSP Healthcare Fund - Direct (G) | 42.22 | 737671 | 2.57 |
DSP Healthcare Fund - Direct (IDCW) | 42.22 | 737671 | 2.57 |
DSP Value Fund (IDCW) | 4.05 | 70785 | 0.61 |
DSP Value Fund - Direct (IDCW) | 4.05 | 70785 | 0.61 |
Load more
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 550.65 560.95 |
Week Low/High | 550.00 605.00 |
Month Low/High | 530.00 625.00 |
Year Low/High | 313.90 646.00 |
All time Low/High | 0.58 1027.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -6.38% | -6.45% | -2.21 | -2.28% |
1 Month | 3.10% | 3.12% | 1.87 | 2.12% |
3 Month | 25.08% | 24.97% | 4.96 | 5.40% |
6 Month | 43.81% | 43.57% | 14.91 | 16.10% |
1 Year | 18.71% | 18.79% | 13.77 | 13.54% |
3 Year | -24.80% | -24.77% | 76.80 | 78.04% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
25-07-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 933060 | 627.89 |
25-07-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 933060 | 628.40 |
24-07-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 643754 | 576.46 |
24-07-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 643754 | 575.88 |
24-07-2023 | NK SECURITIES RESEARCH PRIVATE LIMITED | NSE | BUY | 553535 | 588.25 |
24-07-2023 | NK SECURITIES RESEARCH PRIVATE LIMITED | NSE | SELL | 553535 | 588.59 |
24-07-2023 | QE SECURITIES | NSE | SELL | 505851 | 587.73 |
24-07-2023 | QE SECURITIES | NSE | BUY | 497273 | 587.77 |
24-03-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 723086 | 395.54 |
24-03-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 723086 | 395.14 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 58.70 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 1.96 |
Insurance Companies | 0.08 |
Mutual Funds Uti | 4.63 |
Other Institutional Investors | 0.01 |
Indian Public | 25.35 |
Others Non Institutional Investors | 9.27 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
CMD & Executive Director : Prakash M Patil
ED / MD / Promoter : Rashesh C Gogri
ED / Joint MD / Promoter : Harshit M Savla
E D & Wholetime Director : Harit P Shah
WTD & Executive Director : Uday M Patil
Non Executive Director : Narendra Jagannath Salvi
Independent Non Exe. Director : Navin Chapshi Shah
Independent Non Exe. Director : Krishnacharya G Akamanchi
Independent Non Exe. Director : Priti Savla
Independent Non Exe. Director : Ankit Vikram Paleja
Independent Non Exe. Director : Bhaskar Narayan Thorat
Independent Non Exe. Director : Neha Gada
Registered Office: Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal,Thane,Maharashtra-401506 Ph: 91-22-24072249